Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia

Post time 4 day(s) ago

journal：British Journal of Haematology

Authors：Eitan Kugler; Inbar Cohen; Irina Amitai; Ron Ram; Avraham Frisch; Boaz Nachmias; Jonathan Canaani; Yakir Moshe; Baher Krayem; Shlomzion Aumann; Israel Henig; Vladimir Vainstein; Liat Shargian; Chezi Ganzel; Moshe Yeshurun; Itay Levi; Pia Raanani; Luiza Akria; Yishai Ofran; Shai Shimony; Ofir Wolach

Published date：--

DOI：10.1111/bjh.19548

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.19548

Article link：http://dx.doi.org/10.1111/bjh.19548

Article Source：Wiley。

Remark：

Post time 4 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Wiley] Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia